RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit https://www.indivior.com/ to learn more. Connect with Indivior on LinkedIn by visiting https://www.linkedin.com/company/indivior.
For Further Information
Investors:
Jason Thompson
Indivior Pharmaceuticals, Inc.
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

| Oct-29 |
Indivior Reports Third Quarter 2026 Financial Results
GlobeNewswire
|
| Oct-28 | |
| Oct-22 | |
| Oct-21 | |
| Oct-19 |
Indivior to Report Third Quarter 2026 Financial Results
GlobeNewswire
|
| Sep-29 | |
| Sep-17 | |
| Aug-03 | |
| Aug-03 | |
| Aug-03 |
Supernus jumps premarket on merger deal; GameStop drops
Investing.com
|
| Aug-03 | |
| Jul-31 |
This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108%
Investor's Business Daily
|
| Jul-23 | |
| Jun-25 |
IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects
Investor's Business Daily
|
| May-20 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite